Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||SSHRC Connection Grants: OVPI matching funds opportunity for U of T applicants- Update||$5,000 in matching funds to an applicant's CG application.||The University of Toronto Office of the Vice President, International (OVPI) will support U of T applicants for the SSHRC Connection Grants (CG). To be eligible, CG proposals must have a significant international component (for example, main presenters/participants at a proposed CG event must be U of T researchers, but co-applicants/collaborators are required to be from an international institution, with presenters from outside of Canada).||August 2021 CG competition: July 29, 2021.
For more information, please contact Anett Trifonov, Research Officer, International, firstname.lastname@example.org.
|Tri-Agency||2022 NSERC Discovery Grants||--||The Discovery Grants program assists in: promoting and maintaining a diversified base of high-quality research capability in the natural sciences and engineering in Canadian universities; fostering research excellence; and providing a stimulating environment for research training. Note that all applications must be submitted through U of T; contact: email@example.com.||Sponsor Deadlines:
Mandatory Notice of Intent (NOI): August 3, 2021.
Full Application: November 1, 2021.
|Tri-Agency||CIHR Operating Grant: COVID-19 Vaccine Confidence||Up to $100,000 per year for up to 2 years.||This supports research that will inform effective strategies to improve COVID-19 vaccine confidence and in turn, uptake, among populations experiencing systemic inequities, conditions of marginalization, Indigenous Peoples and/or among populations who are historically under-vaccinated.||August 10, 2021.|
|Tri-Agency||New Frontiers in Research Fund (NFRF) 2021 Exploration Competition||Up to $100,000 per year for direct costs (plus $25,000 per year for indirect costs) for up to 2 years.||The goal of the Exploration stream is to inspire high-risk, high-reward and interdisciplinary research. Exploration grants support research that pushes boundaries into exciting new areas. Researchers are encouraged to think "outside of the box", undertake research that would defy current paradigms, and bring disciplines together in unexpected ways and from bold, innovative perspectives. Please stay tuned for deadlines for internal review of the full application.||Notice of Intent: August 10, 2021.
Full Application: Internal, TBA; Sponsor, October 19, 2021.
|Tri-Agency||CIHR Operating Grant: Emerging COVID-19 Research Gaps & Priorities July 2021||Up to $1,000,000 for 1 year for a clinical trial or RCT; Up to $500,000 for 1 year for all other types of research.||The purpose is to provide rapid funding for projects which respond to identified gaps in COVID-19 research areas. To be eligible to the competition, applications must address both objectives AND respond to one of the eleven specific research areas. Please see details of the objectives and research areas on the funding opportunity website.||Registration: August 10, 2021.
Application: September 14, 2021.
|Tri-Agency||CIHR Team Grant: Healthy Cities Implementation Science (HCIS) Team Grants||Development & Engagement: Up to $25,000 for up to 1 year.|
Full Grant: Up to $500,000 per year for up to 6 years.
|These grants will be focused on increasing our understanding of how to design, implement and promote the systematic and equitable uptake of evidence-based interventions (i.e. interventions that have been piloted or tested in a setting and found to be promising) in multiple urban environments to improve population health and well-being. Proposed research projects must be relevant to at least one of the following thematic areas but may also be relevant to multiple thematic areas: Healthcare systems, services and policies; Healthy aging; Musculoskeletal health, mobility or prevention (including skin and oral health); Type 2 diabetes prevention; Urban Indigenous health; Population and public health.||Letter of Intent: August 11, 2021.
Full Application (by invitation): April 28, 2022.
|Tri-Agency||CIHR Project Grant: Fall 2021||Project Grant funding levels are proportionate to the requirements of the research proposed, which is expected to vary by research field, research approach, and scope of proposal activities.||The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, health care, health systems, and/or health outcomes by supporting projects or programs of research proposed and conducted by individual researchers or groups of researchers in all areas of health. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.||Registration: August 18, 2021.
Application: September 15, 2021.
Please select Unity Health Toronto as your institution
Save the Date: VPRI Office plans to hold an informal Q&A session on August 20, 2021 at 2pm-3pm via Zoom. Please stay tuned for details.
|Tri-Agency||SSHRC Partnership Engage Grants||$7,000 to $25,000 for 1 year||Partnership Engage Grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. The small-scale, stakeholder-driven partnerships supported through the Partnership Engage Grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors.||September 1, 2021|
|Tri-Agency||NFRF Special Call: 2021 Innovative approaches to research in the pandemic context||$250,000 (includes $50,000 indirect costs) over 1 year, an automatic one-year extension will be available.||The goal of this rapid response call is to accelerate the exploration of new approaches and the development and testing of new directions in research methodologies. It is expected that this call will predominately support new ways of conducting community and field-based research, since the pandemic has had the greatest impact on researchers' ability to collect data and conduct this type of research. For this call, it is not required for projects to be interdisciplinary. Applications must propose the development of a new way of doing research.||Notice of Intent (NOI): September 21, 2021.
Full Application: October 26, 2021.
Webinars: French-August 12, 2021, 10 a.m. to 12 p.m. ET via WebEx: Link; Password: pbVE336Nmpy. English-August 12, 2021, 1 p.m. to 3 p.m. ET via WebEx: Link; Password: CPmZji4aJ23
|Tri-Agency||NSERC Idea to Innovation Grants (I2I Grants)||Market Assessment: up to 12 months, $15,000; |
Phase I: up to 12 months, $125,000;
Phase Ib: up to 6 months, $60,000;
Phase IIa: from 6 to 18 months, $125,000;
Phase IIb: up to 24 months, $350,000
|The objective of the Idea to Innovation (I2I) grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established Canadian company.||September 27, 2021.|
|Tri-Agency||SSHRC Insight Grants: October 2021 Competition||Stream A: $7,000 to $100,000; Stream B: $100,001 to $400,000. Duration 2-5 years.||Insight Grants support research excellence in the social sciences and humanities. Insight Grants support research proposed by scholars and judged worthy of funding by their peers and/or other experts. Insight Grant research initiatives can be undertaken by an individual researcher or a team of researchers working in collaboration.||October 1, 2021.|
|Tri-Agency||CIHR Team Grant: Sleep Research Consortium||--||This supports a Sleep Research Consortium focused on sleep hygiene and insomnia through the lifecycle. The Consortium will have a broad mandate that includes expertise across the CIHR research pillars (i.e., biomedical/basic; clinical; health systems services; and population health), multiple sectors (e.g., government, charities/not-for-profits, and private organizations/industry), multiple stakeholders (e.g., communities, people with lived/living experience, families, caregivers), Indigenous Peoples (First Nations, Inuit or Métis, including Urban Indigenous communities); and focused on co-creating new knowledge and mobilizing knowledge to improve health outcomes as they relate to insomnia and sleep deprivation.||Registration: October 5, 2021.
Application: January 13, 2021.
CIHR Webinar: September 8, 2021 at 11:00 am ET , Join
|Tri-Agency||SSHRC Pre-Announcement: Race, Gender and Diversity Initiative||Up to $450,000 for up to 3 years.||This will support community-based and community-led research, carried out in partnership with postsecondary institutions, that is based on the lived experience of underrepresented and disadvantaged groups, including but not limited to women; First Nations, Inuit and Métis Peoples; Black, Asian and other racialized peoples; people living with disabilities (both visible and invisible); LGBTQ2+ people; religious minorities; and others marginalized on the basis of their ethnicity and other identity factors, as well as individuals who identify as, or belong to, more than one of these groups.||Anticipated Deadlines: Details TBA when launched in Summer 2021.|
|Tri-Agency||CIHR Pre-Announcement: Transitions in Care - Team Grants Phase 2||Up to $240,000 per year for up to 4 years.||This will support inter-disciplinary teams that are poised and ready to optimize health outcomes during transitions in care. The grants will provide support to develop, implement, evaluate, and equitably spread and/or scale (share) pragmatic solutions to challenges associated with transitions in care from a clinical, health care or health system perspective. Applicants are required to have a health system partner.||Anticipated Timelines:
Program Launch: Summer 2021
Applicant Webinar: Fall 2021
Application Deadline: Winter 2022
|Tri-Agency||CIHR Pre-Announcement: Accelerate Evidence on Health Care Delivery System Innovations that Achieve the Quadruple Aim and Improve Health Equity Catalyst Grants||Up to $100,000 for 1 year.||The Quadruple Aim centres on four overarching goals: are improved population health outcomes, improved care and patient experience, improved provider satisfaction, and lower costs / better value. This opportunity will fund one-year knowledge creation (knowledge synthesis, comparative policy analysis, or evaluation grants) and knowledge implementation (scale and spread grants, or focused implementation grants) projects aligned to one or more of the relevant research areas identified at the opportunity website.||Anticipated Timelines:
Launch: Summer 2021.
Application Deadline: Fall 2021
|Tri-Agency||CIHR Pre-Announcement: SPOR Primary Care Network||$10,000,000 over 5 years.||The aim of this funding opportunity is to support the development of a national SPOR Primary Care Network that will facilitate the reach, adaptation, and accessibility of successful patient-oriented primary and integrated health care innovations to new sites, new settings, and/or new populations. The Network will mobilize knowledge to inform and transform practice, clinical care, policy, and/or decision-making toward more optimal and equitable health outcomes. Through research, training, mentorship, collaborations and partnerships, the Network will build capacity for the ongoing application of patient-oriented primary and integrated health care knowledge.||Anticipated Timelines*:
Program Launch: August 2021
Application Deadline: December 7, 2021.
*These timelines are estimates and subject to change.
|Tri-Agency||CIHR Pre-Announcement: SPOR Networks - Knowledge Mobilization and Implementation Science Grants||Up to $3,750,000 over 4 years.||The aim of this funding opportunity is to mobilize and apply the knowledge generated in Phase 1 to improve healthcare systems and practices, to conduct research with a focus on implementation science, to support patient-oriented research capacity building and partnerships, and, ultimately, contribute to equitable health outcomes. This funding opportunity is directed to the following SPOR Chronic Disease Networks: CHILD-BRIGHT Network; Chronic Pain Network; Diabetes Action Canada; Inflammation, IMAGINE-SPOR Chronic Disease Network; Can-SOLVE CKD.||Anticipated Timelines*
Program Launch: August 2021
Application Deadline: November 9, 2021
*These timelines are estimates and subject to change.
|Tri-Agency||NSERC Alliance/Mitacs Accelerate Grants||--||This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.||Ongoing|
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||U of T - University of Melbourne (UoM) International Research Training Group (IRTG) Grant Applications||Up to CAD $34,000 CAD (total) from U of T; Up to CAD $29,000 per year from UoM.||This call is for proposals from all research areas to establish joint PhD projects. UoM and U of T faculty awarded funding under this call will be expected to jointly recruit and co-supervise PhD candidates on approved PhD project proposals. Priority will be given to "Cluster Applications" which includes 3 or more primary supervisors (across both institutions) supervising at least 2 joint PhD candidates.||August 16, 2021.|
|Other Canadian||Canadian Foundation for Dietetic Research (CFDR): 2022 Research Grant Competition||Up to $20,000.||Priority research directions for the 2022 CFDR grants are outlined in the five category descriptions at the 2022 Research Grant website. CFDR strongly encourages applications from First Nations, Métis and Inuit peoples, racialized persons and those who identify as 2SLGBTQ+. Preferences will be given to project submissions that reflect a collaborative approach to research.||Letter of Intent: September 20, 2021.
Proposal (by invitation): March 4, 2022.
|Other Canadian||Unity Health Internal Call for Expressions of Interest (EoI): CFI Innovation Fund 2023||--||As communicated by email to all appointed researchers on June 22, VPRI Office is running an internal process in advance of the 2023 Innovation Fund competition. The purpose of this process is to identify projects that will be funded from Unity Health's institutional 'envelope' of available CFI support. The CFI IF supports infrastructure only. Priority will be given to projects that demonstrate a major "value-add" for the institution.||If you are interested in submitting an EoI by September 24, 2021, please contact Erica.Conte@unityhealth.to ASAP for a copy of the EoI form.|
|Other Canadian||Ontario Early Researcher Awards (ERA) Program - Round 16||--||The ERA Program funds full-time new researchers to build a research team. The submission must go through the institute, and has an internal peer review process and internal timelines.||If you are interested in applying, email VPRI@smh.ca. ASAP so we can forward the application materials and internal deadlines.|
|Other Canadian||2021-2022 St. Michael's Hospital Medical Services Association Alternate Funding Plan (SMHA AFP) Innovation Fund Request for Proposals||--||The SMHA AFP provides short-term (1 year or 2 year) seed funding to support innovative projects and to enable academic physicians to develop programs sufficiently to qualify for additional support and evaluate novel strategies to transform health-care delivery in Ontario. This competition is open to all SMHA AFP participating physicians. Please contact your local practice plan to determine process and timelines for new project submissions. If there are any questions regarding this competition, please do not hesitate to contact Marcos Pinto, SMHA Business Manager (Marcos.Pinto@unityhealth.to) or Dr. Kenneth Pace, SMHA Chair (Kenneth.Pace@unityhealth.to).||--|
|Other Canadian||Mitacs Accelerate: Eligibility and New Program Updates||--||Options and enhancements include expanding eligibility for both interns and external sponsoring partners, and increasing support levels for some partners.|
Mitacs Accelerate-Expanded Eligibility Criteria: Mitacs can now support undergraduate students as interns on a Mitacs Accelerate grant. In addition, municipalities and hospitals are now considered to be eligible partner organizations for Mitacs Accelerate
Mitacs SME Discount Model:Until February 1, 2022, a partner organization that is a small/medium-sized enterprise (SME) in the for-profit or non-profit sector will only be charged 25% of the overall project costs instead of Mitacs's typical 50% cost-sharing ratio. Details here: Link.
Accelerate Industrial Post-Doctoral Fellowship-New Funding Model: This funding stream provides $60,000/year for a post-doctoral fellow, where the partner organization must contribute $30,000 plus applicable taxes per year. Details here: Link.
Mitacs and National Research Council (NRC) collaborative funding stream for R&D projects: Support for 250 graduate and post-graduate student internships within the NRC's Challenge and Supercluster support programs. Details here: Link.
|Other Canadian||Pre-Announcement: New Digital Research Infrastructure Organization (NDRIO) Inaugural Funding Opportunity (IFO)||Funding Stream 1: $100,000 to $1M; Funding Stream 2: $1M to $3M.||The IFO aims to build national research capacity and deliver on NDRIO's mandate to create a broad and integrated Canadian digital research infrastructure (DRI) ecosystem. Specifically, the IFO will address the needs of the research community related to DRI, while promoting an equitable and inclusive DRI environment in Canada. The IFO will be open to proposals from all research disciplines, and with strong encouragement for inter-provincial collaborations and multi-disciplinary partnerships.||Tentative Deadlines: To be confirmed when competition opens on May 1, 2021.
Letter of Intent: Opens May, 2021. Reviewed and selected July-August, 2021.
Full Proposal (by invitation): Opens September, 2021. Adjudicated January-March, 2022.
If you are interested in applying for this opportunity, please let us know by email to VPRI@smh.ca.
|Other Canadian||University of Toronto Institutional Strategic Initiatives (ISI)||From $50,000-$300,000 per year for up to 3 years.||ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding.||Ongoing.|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to ).
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY21 Peer Reviewed Cancer Research Program (PRCRP): Various Opportunities||Behavioral Health Science Award: Up to USD $1 million for up to 4 years.|
Career Development Award - Fellow Option: Up to USD $400,000 for up to 3 years.
Translational Team Science Award: Up to USD $2.5 million for up to 4 years.
|Applications must address one or more of the FY21 PRCRP Topic Areas listed in the funding opportunities. Research applications in the areas of breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, or melanoma are prohibited are prohibited and will not be accepted.|
Behavioral Health Science Award: Preliminary data are required, pilot clinical trials are allowed.
Career Development Award - Fellow Option: PI must be at or above the level of Assistant Professor (or equivalent) and within 7 years after completion of their terminal degree. Preliminary data are not required, clinical trials are not allowed.
Translational Team Science Award: Preliminary data are required, clinical trials are allowed.
|Behavioral Health Science Award: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Career Development Award - Fellow Option: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
Translational Team Science Award: Deadlines: Pre-Application- July 29, 2021. Application- August 18, 2021.
|International||BrightFocus Foundation Macular Degeneration Research Program: Various Opportunities||New Investigator Grant Program: Up to USD $450,000 for up to 3 years.|
Innovative Research Grants: Up to USD $600,000 for up to 3 years.
|New Investigator Grant Program: For investigators who have received their MD, PhD or equivalent degree within the past 10 years at the time of application.|
Innovative Research Grants: For high-risk/high-gain age-related macular degeneration research. Established investigators are encouraged to apply for this support.
|Letter of Intent: July 29, 2021.
Full Application (by invitation): December 3, 2021.
|International||Heart and Stroke Foundation of Canada (HSFC) 2022/23 Heart & Stroke Research Competitions: Various Opportunities||New Investigator: $60,000 per year for up to 3 years.|
Grants-in-Aid (GIA): Up to $100,000 per year for up to 3 years.
|New Investigator: Provides salary support to individuals who have clearly demonstrated excellence during their doctoral and post-doctoral training in cardiovascular or cerebrovascular research. No more than five (5) years may have passed since the date of the first faculty appointment at the Assistant or Clinical Assistant Professor level. |
Grants-in-Aid (GIA): This provides operating funds to support important, pertinent, novel research in the areas of heart disease and stroke.
|New Investigator: Registration: July 29, 2021; Application: September 2, 2021.
Grants-in-Aid (GIA): August 26, 2021.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Chronic Pain Management Research Program (CPMRP)||Clinical Exploration Award: Up to USD $250,000 for up to 2 years.|
Investigator-Initiated Research Award: Up to USD $900,000 for up to 4 years.
Translational Research Award:: Up to USD $1.4M for up to 4 years.
|Clinical Exploration Award: Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers. |
Investigator-Initiated Research Award: Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life.
Translational Research Award: Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications.
|Pre-Application: July 30, 2021
Application (by invitation): November 12, 2021.
|International||Society of Critical Care Medicine (SCCM) Research Grants||SCCM-Weil Research Grant:USD $50,000 for up to 18 months.|
Discovery Research Grant: USD $100,000 for up to 12 months.
|SCCM-Weil Research Grant: Awarded to SCCM Professional or Select members for basic, translational, or clinical research. Single-site clinical study. |
Discovery Research Grant: Awarded to SCCM Professional or Select members for a Multi-institutional study (collaboration between at least two institutions).
|August 1, 2021.|
|International||Pfizer Global Medical Grants (GMG) Pfizer Innovation Challenge Request for Proposals (RFP): Patient Preference Database Blueprint||Up to USD $50,000.||This solicits proposals to develop a blueprint for collating, organizing, and storing publicly available results from multiple patient preference studies, such as may be found in publications or study reports in a single database, organizing results by disease, treatment class, patient type, etc. or any other categorization scheme and propose a method for extracting and synthesizing available data so that the existing quantitative preference estimates can be used as weights in decision-analytic models as an alternative to de novo primary data collection.||August 2, 2021.|
|International||Association for Academic Surgery (AAS): Joel J. Roslyn Faculty Research Award||USD $50,000 for 1 year.||Intended to provide early-career research support to junior faculty members of the AAS. Applicants must be full-time faculty who have not yet attained the rank of Associate Professor. Faculty in any surgical specialty or discipline are eligible.||August 2, 2021.|
|International||American Foundation for Suicide Prevention (AFSP): Grant Cycle 2021-2022||Focus Grant-Blue sky research grant: Up to USD $500,000 per year for up to 3 years.|
Linked Standard Research Innovation Grants: Up to USD $450,000 per year for up to 2 years.
Distinguished Investigator Innovation Grants: Up to $125,000 over 2 years.
Standard Research Innovation Grants: Up to $100,000 over 2 years.
Young Investigator Innovation Grants: Up to $90,000 over 2 years.
Pilot Innovation Grants: Up to $30,000 over 2 years.
|Focus Grant-Blue sky research grant: Supports an innovative, impactful study in an area of suicide research that will achieve significant goals. This mechanism is intended for studies that, by their very nature, are clearly beyond the financial scope of our Innovation Grants. |
Linked Standard Research Innovation Grants: For research involving two or more unique sites with each site contributing unique expertise, as well as data collection.
Distinguished Investigator Innovation Grants: For investigators at the level of associate professor or higher with an established record of research and publication on suicide.
Standard Research Innovation Grants: Grants awarded to individual investigators at any level.
Young Investigator Innovation Grants: Grants awarded to investigators at or below the level of assistant professor.
Pilot Innovation Grants: These provide seed funding for new projects that have the potential to lead to larger investigations. These grants typically entail feasibility studies rather than hypothesis-driven research.
|Focus Grant-Blue sky research grant: Letter of Intent: August 1, 2021; Full Application (by invitation): December 7, 2021.
Linked Standard Research Innovation Grants: Letter of Intent: September 15, 2021; Full Application (by invitation): November 15, 2021.
Distinguished Investigator Innovation Grants: November 15, 2021.
Standard Research Innovation Grants: November 15, 2021.
Young Investigator Innovation Grants: November 15, 2021.
Pilot Innovation Grants: November 15, 2021.
|International||American Society of Colon and Rectal Surgeons (ASCRS) Research Foundation: Various Opportunities||Research in Robotic Surgical Technology Grants: USD $50,000 for 1 year; Up to USD $100,000 for 1 year for collaborative proposals that include 2 or more institutions. |
International Fellowship Grants: USD $12,500 for 1 year.
General Surgery Resident Research Initiation Grants: USD $20,000 for 1 year.
|Research in Robotic Surgical Technology Grants: This is for research interests specifically germane to robotic surgical technology in the field of colon and rectal surgery. |
International Fellowship Grants: This grant will focus on providing support to clinical investigators in the United States or Canada who would like to participate in research outside the United States or Canada.
General Surgery Resident Research Initiation Grants: Applicants must be General Surgical Residents or recent (within 2 years) Graduates of a US or Canadian approved General Surgery Training Program.
|Research in Robotic Surgical Technology Grants: August 15, 2021.
International Fellowship Grants: August 15, 2021.
General Surgery Resident Research Initiation Grants: August 15, 2021.
|International||Biogen: Various Opportunities||--||Biogen considers requests across a variety of disease areas including Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Biosimilars (Crohn's Disease and Rheumatoid Arthritis), Multiple Sclerosis, and Spinal Muscular Atrophy. The Biogen website lists the specific areas of interest for each opportunity below:|
- Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
- Patient Education: Supports independent educational activities for patients or caregivers.
- General Grant: Supports a project or program that does not fit any of the other defined grant categories.
|August 15, November 1.|
|International||American Society of Cytopathology Foundation (ASC Foundation) Patient Advocacy Grant||USD $10,000.||The ASC has had an increased emphasis on public education and awareness and understands the need to adopt early detection practices - especially for women regarding cervical cancers. This grant is for ongoing or new projects for advocacy efforts for patients with gynecologic and other cancers, or to educate patients on the need for effective screening programs.||August 15, 2021.|
|International||Pfizer Global Medical Grants (GMG): Pfizer and Lilly Request for Proposals (RFP) Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain||Up to USD $200,000.||This support virtual and potentially live programs and other innovative digital medical education for HCPs. The focus is on Osteoarthritis (OA) and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.||The RFP will open while funds last. Review deadlines for 2021 is August 20, 2021.|
|International||Pfizer Global Medical Grants (GMG) Request for Proposals (RFP): Antimicrobial Stewardship (AMS) Programs to Address Health Inequities in Resource Limited Settings||Up to USD $100,000 for up to 24 months.||This RFP is to solicit programs that have identified a disparity that impacts antimicrobial stewardship in a resource-limited setting and proposes an intervention to address the disparity to improve and measure patient outcomes.||August 26, 2021.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Breast Cancer Research Program (BCRP): Various Opportunities||Breakthrough Award Levels 1 and 2: Level 1 Value: Up to USD $450,000 or up to USD $750,000 (Partnering PI) for up to 3 years. Level 2 Value: Up to USD $1M or $1.5M or up to USD 1.5M or $2.0M (Partnering PI) for up to 4 years. |
Era of Hope Scholar Award: Up to USD $3M for up to 4 years.
|Breakthrough Award Levels 1 and 2: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. |
Era of Hope Scholar Award: Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.
|Breakthrough Award Levels 1 and 2:
Pre-Application: August 31, 2021
Application: September 14, 2021.
Era of Hope Scholar Award:
Pre-Application: August 31, 2021
Application: September 14, 2021.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Combat Readiness - Medical Research Program (CRRP) Rapid Development and Translational Research Award)||Phase 1 Base: Up to USD $1.8M total costs for up to 2 years; |
Phase 1 Base + Phase 2 Option: Up to USD $1.8M total costs for up to 2 years + $1.0M total costs for up to 1 year.
|This considers research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma. Applications must address one or more of the following Focus Areas: Solutions to enhance Warfighter readiness; Solutions to enhance combat care delivery throughout the far-forward environment; Wound-care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care.||Pre-Application: August 31, 2021.
Application (by invitation): December 1, 2021.
|International||Merck 2021 Research Grants||40,000 € - 450,000 € per year for up to 3 years.||Merck is offering a series of research grants to stimulate innovative research in: Drug Discovery; Real time testing and sensors; Nanoparticles for nucleic acid delivery; Digital Innovation; Biooelectronics; Sustainability; Media recycling for cultured meat; Organoids.||August 31, 2021.|
|International||Bristol-Myers Squibb/Pfizer Alliance Education Request for Proposals (RFP) in Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)||Up to USD $150,000.||Grant proposals can address either AF or VTE or both areas. Projects that will be considered for support will focus on improving the care of patients by addressing knowledge gaps in the areas listed on the RFP website, including, but not limited to: updates on anticoagulation guidelines/guidance, anticoagulation in special populations, bleeding and thrombosis risk assessment through patient characteristics.||Accepted on a rolling basis until September 1, 2021. This RFP will remain open while funds last.|
|International||Wings for Life (WFL) Spinal Cord Research Foundation: Various Opportunities||Individual Grants: Up to EUR 57,000€ per year for up to 3 years.|
Project Research Grants: Up to EUR 100,000€ per year for up to 3 years.
|WFL grants promote basic and clinical research related to spinal cord injury with the perspective to improve outcomes.|
Individual Grants: Intended only to cover the salary of the applicant: Post-docs, PhDs, and/or technicians.
Project Research Grants: Intended to sustain a full research project.
Accelerated Translational Program (ATP) (clinical trials): Specifically designed to be able to accommodate obstacles to efficient clinical translation.
|Individual Grants: Executive Summary: September 1, 2021; Full Application: November 2, 2021.
Project Research Grants: Executive Summary: September 1, 2021; Full Application: November 2, 2021.
Accelerated Translational Program (ATP) (clinical trials): Continuous submission.
|International||Concern Foundation for Cancer Research CONquer canCER Now Award||USD $60,000 per year for up to 2 years.||Eligible applicants are independent investigators who are at the start of their scientific career (i.e., junior faculty) and are at the level of Assistant Professor. Successful proposals are usually from investigators who have been in their independent position and directing their own research program for more than one year. Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology. This will not fund clinical trials, cancer epidemiology, or behavioral studies.||Pre-Eligibility Questionnaire: September 6, 2021.
Letter of Intent (LOI): September 8, 2021.
Full Proposal (by invitation): February 1, 2022.
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) Multiple Sclerosis Research Program (MSRP)||Early Investigator Research Award: Up to USD $200,000 for up to 2 years.||Early Investigator Research Award ||Early Investigator Research Award: Pre-Application: September 7, 2021; Application: October 1, 2021.
|International||Fondation Leducq International Networks of Excellence in Cardiovascular and Neurovascular Research Program (INEP)||USD $7,500,000 over 5 years.||Formerly the Transatlantic Networks of Excellence Program (TNE), this which promotes internationally collaborative basic, translational, and clinical research Coordinators under the INEP may come from any country, as long as the two coordinators of the network are from different continents.||Letter of Intent: September 7, 2021.
Full Application (by invitation): February 14, 2022.
|International||Massage Therapy Foundation (MTF) Research Award||Between USD $30,000-$300,000.||This supports high quality, independent research that contributes to the basic science of massage therapy application, including applied research investigating massage therapy as a health/mental health treatment and/or prevention modality.||Pre-Proposal: September 10, 2021.
Full Proposal (by invitation): December 6, 2021.
|International||March of Dimes 2022 Research Grants||Between USD $200,000-$300,000 for 24-36 months.||This seeks applications that involve translational and actionable science that will lead directly to interventions or preventions. The goal is to turn observations in the laboratory, clinic, and community into interventions, therapeutics, and diagnostics that improve the health of moms and babies. The proposed research should focus on one of these priority areas: Pregnancy-related disorders that lead to spontaneous or medically indicated premature birth; Developmental origins of infant health; Maternal morbidity & mortality, including social determinants and drivers of health.||September 10, 2021.|
|International||American Thoracic Society (ATS) Research Program - Various Opportunities||Nursing Research Grant: USD $45,000 for 1 year.|
Unrestricted Grants: USD $40,000 for 1 year.
Partner Grants: USD $40,000 - $50,000 per year. Please see website for details.
|ATS accepts submissions by international and domestic applicants unless otherwise specified.|
Nursing Research Grant: These grants are for licensed registered nurses with a PhD interested in pulmonary, critical care, and sleep medicine. Applicants must not be more than 12 years beyond their terminal degree.
Unrestricted Grants: These grants are for investigators within 12 years of terminal degree (e.g. MD, PhD). Grants will be awarded in each of the three pillars: pulmonary, critical care, and sleep medicine.
Partner Grants: These grants are offered in partnership with ATS Research Program's partners to support disease-specific research grants. Please see website for details.
|Letter of Intent: September 14, 2021.
Application (by invitation): January 1, 2022.
|International||ZOLL Foundation||Typically in the USD $10,000-$50,000 range.||This invites studies in the fields of resuscitation or acute critical care that aim to improve practices, prevent patient deterioration, reduce mortality and morbidity, or address some other aspect of enhancing care. Grant applicants should be newer researchers, ideally recommended by a more established investigator.||September 30, 2021; March 31, 2022.|
|International||ResMed Foundation Grants||Physician and Public Awareness Proposals: USD $10,000.|
Clinical Research Proposals: USD $250,000.
| Physician and Public Awareness Proposals: To further the awareness and knowledge of the inherent dangers of untreated SDB, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.|
Clinical Research Proposals: The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of sleep disordered breathing (SDB) and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. The Foundation is also interested in the application of novel screening and diagnostic tools to identify more easily SDB/OSA, as well as new and better paradigms to improve patient adherence and compliance with positive airway pressure and ventilation-based treatment methods.
|Physician and Public Awareness Proposals: December 15, 2021.
Clinical Research Proposals: September 15, 2021.
|International||Thoracic Surgery Foundation (TSF): Various Opportunities||TSF Research Award: Up to USD $50,000 per year for up to 2 years.|
Nina Starr Braunwald Research Award: Up to USD $50,000 per year for up to 2 years.
TSF Every Heartbeat Matters Awards: Up to USD $37,500.
|TSF Research Award: This supports the work of an early-career cardiothoracic surgeon who is within 7 years of their first faculty appointment. |
Nina Starr Braunwald Research Award: This supports the work of an early-career woman cardiac surgeon (within 5 years of first faculty appointment).
TSF Every Heartbeat Matters Awards: This supports: Programs that educate, screen and/or treat underserved populations to reduce the global burden of heart valve disease and; Other programs that advance health care and address underserved populations. This can include education and awareness campaigns, research, and/or direct care for underserved populations.
|September 15, 2021.|
|International||Laerdal Foundation for Acute Medicine||NOK 250,000 (USD ~$30,000) for 1 year.||The Laerdal Foundation focuses on practically oriented research. "The Chain of Survival" and "The Utstein Formula for Survival" have been established as metaphors for understanding system factors that impact the chances of survival. The Foundation Board wishes to contribute to a continued documentation and validation on how these concepts may reflect current medical, educational and implementation science. There, in particular, is a need for improved understanding of factors contributing to educational efficiency and the process of implementing scientific evidence into practice.||October 1, 2021.|
|International||American Academy of Neurology (AAN) Research Program: Career Development Award (CDA)||USD $150,000 per year for 3 years.||This supports junior investigators interested in an academic career in clinical, basic, or translational neurological research. Recipient must be a neurologist and an AAN member interested in an academic career in neurologic research who completed residency between 5-10 years prior to the start date of the Career Development Award (July 1, 2022).||October 1, 2021.|
|International||Morton Cure Paralysis Fund (MCPF) Research Grant||USD $5,000 to $75,000 for 1 year.||This funds activities that hold promise of identifying therapies (cures) for paralysis in humans. MCPF has particular focus of enabling scientists to develop the proof concept data necessary to apply for larger grants. The focus areas are: |
1. Understanding the effects of spinal cord injury at the cellular level, particularly with emphasis on that which determines apoptosis and/or prohibits regrowth.
2. Studying strategies to promote neuronal growth and survival, encourage the formation of synapses, enhance the production of myelin, restore conduction capabilities, or otherwise lead to restoration of the compromised circuitry in the acutely and chronically injured CNS.
3. Evaluating new therapies in clinical trial.
|October 31, 2021.|
|International||Mendez National Institute of Transplantation Foundation (MNITF) Research Grant Program (RGP)||USD $50,000 - $100,000 for 1 year.||These grants support innovative research to advance the science and practice of organ transplantation. Research in the following areas is considered: clinical outcomes in transplantation; donor screening technologies, immunogenetics, post-transplant monitoring, and advancements in regenerative medicine; new diagnostic and therapeutic paradigms; empowering patients with end-stage organ disease and transplant recipients through education to proactively manage their health and improve their long-term outcomes.||Letter of Intent: November 1, 2021.
Application (by invitation): July 31, 2021; December 15, 2021.
|International||Foundation for Physical Medicine & Rehabilitation (FPM&R) Mid-Career Research Grant||USD $25,000.||This is a short-term grant for research in topics related to the field of physical medicine and rehabilitation. Eligible applicants for grant include any physiatrist or faculty member in a division or department of physical medicine and rehabilitation who is at least 5 and not more than 20 years post-completion of a terminal degree and subsequent training program.||November 1, 2021.|
|International||Orthopaedic Research Society (ORS): ON/ORS Kick-Starter Grants||USD $10,000||This supports ORS members' research that focuses on an innovative approach in regenerative orthopaedics or that answers an important open question in that field. The topic is innovative scaffolds for the regeneration of musculoskeletal tissues.||November 2, 2021.|
|International||ResMed Foundation: Physician and Public Awareness||USD $10,000.||This is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. Only programs that have wide outreach to a significant clinical or public population base will be considered.||December 15, 2021.|
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY21 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)||Clinical Research Development Award: Up to USD $300,000 total costs for up to 2 years.|
Clinical Trial Award: Funding Level 1: Up to USD $750,000 total costs for up to 3 years; Funding Level 2: Up to USD $3M total costs for up to 4 years; Funding Level 3: Up to USD $6M total costs for up to 4 years.
Focused Program Award: Up to USD $8M total costs for up to 4 years.
Idea Development Award: Up to USD $300,000 total costs for up to 2 years.
Investigator-Initiated Research Award: Up to USD $750,000 total costs for up to 3 years.
Translational Research Award: Up to USD $1.5M total costs for up to 3 years.
|Clinical Research Development Award: Supports planning and development activities necessary to initiate a future clinical study. |
Clinical Trial Award: Supports clinical trials for pharmacological (e.g., biologics, drugs) and non-pharmacological (e.g., devices, psychotherapy) interventions.
Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
Idea Development Award: Supports innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications.
Investigator-Initiated Research Award: Supports research with the ability to make an original and important contribution to research and/or patient care.
Translational Research Award: Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation) and clinical care (i.e., implementation science).
|International||Pfizer Global Medical Grants (GMG): COVID-19 Vaccine Grants||--||COVID-19 Vaccine General Research (now open): Pfizer is accepting COVID-19 general research grant requests that address the following areas: Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.|
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.
COVID-19 Vaccine Independent Medical Education (coming soon): Optimize the prevention of COVID-19 by:
- Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
- Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.
|Vaccine General Research: Rolling submission.
Independent Medical Education: TBA
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research.||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|NIH||NIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)||--||The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.||August 10, 2021; March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.|
|NIH||New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service|
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
|--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|August 11, 2021; November 18, 2021; August 11, 2022; November 18, 2022; August 11, 2023|
|NIH||NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies||--||National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.|
National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
|This notice applies to due dates on or after September 5, 2021 and subsequent receipt dates through May 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide||--||This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.||This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)||--||This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.||September 7, 2021; July 14, 2022; September 7, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities||--||This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.||This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)||--||The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.||September 8, 2021; January 10, 2022; September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.|
|NIH||Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention|
- PA-18-861 (R03 - Clinical Trial Optional)
- PA-18-862 (R21 - Clinical Trial Optional)
- PA-18-863 (R01 - Clinical Trial Optional)
|--||The purpose is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.||Standard dates apply until September 8, 2021 (R21, R01) or January 8, 2022 (R03).|
|NIH||Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2||--||This NOSI encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:|
- SARS-CoV-2 candidate vaccines
- non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
- therapeutic approaches to treat COVID-19
|Applications will be accepted once a month through September 14, 2021.|
|NIH||NIH High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)||--||This will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway). Applicants may also propose secondary screens and/or validation of high value identified targets.||September 15, 2021.|
|NIH||NIH Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)||--||These support applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).|
RFA-AG-22-016 (R61/R33 Clinical Trial Required): Supports pilot research (R61) to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to an R33 phase for implementation of rigorous, proof-of-concept intervention studies. Deadline: September 15, 2021.
PAR-21-207 (R01 Clinical Trial Optional): Specifically supports ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study. Deadlines: September 15, 2021; January 26, 2022.
|RFA-AG-22-016 (R61/R33 Clinical Trial Required): September 15, 2021.
PAR-21-207 (R01 Clinical Trial Optional): September 15, 2021; January 26, 2022.
|NIH||NIH Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches: Various Opportunities||--||This solicits applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. |
PAS-21-215 (R21 Clinical Trial Optional): For exploratory, smaller scope, highly-innovative projects. Deadline: October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): For projects that require more time, a more flexible budget, and are larger in scope. Deadline: October 5, 2021.
|PAS-21-215 (R21 Clinical Trial Optional): October 16, 2021.
PAS-21-216 (R01 - Clinical Trial Optional): October 5, 2021.
|NIH||NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions||--||National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.||This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research||--||The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.||This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.|
|NIH||NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.||October 13, 2021; February 9, 2022; June 9, 2022; October 11, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.|
|NIH||NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application.||October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.||October 13, 2021, June 9, 2022, October 11, 2022, June 9, 2023, and October 10, 2023.|
|NIH||Single-Site Investigator-Initiated Clinical Trials (R61/R33)||--||This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)||--||This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||October 14, 2021; February 11, 2022; June 10, 2022|
|NIH||NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities||--||NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.|
PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
|October 15, 2021; February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.|
|NIH||NIH Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 - Clinical Trial Optional)||--||This will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of cardiovascular disease (CVD) in Type 1 Diabetes Mellitus (T1DM), and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.||October 15, 2021.|
|NIH||NIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)||--||This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.||October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.|
|NIH||NIH HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose: Various Opportunities||--||These support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities.|
RFA-DA-22-031 (R01 Clinical Trial Not Allowed): Applicants with preliminary data may wish to apply to this R01. High risk/high payoff projects that lack preliminary data are most appropriate for the companion R21.
RFA-DA-22-032 (R21 Clinical Trial Not Allowed): High risk/high payoff projects that lack preliminary data are most appropriate for this R21. Applicants with preliminary data may wish to apply for the companion R01.
|October 19, 2021.|
|NIH||National Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.||October 20, 2021; February 22, 2022; June 21, 2022|
|NIH||NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)||--||This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.||October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.|
|NIH||Neural Regulation of Cancer|
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
|--||These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.||October 21, 2021; May 27, 2022|
|NIH||NIH Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)||--||This is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative will support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative will leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples.||Deadlines: November 3, 2021.|
|NIH||NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)||--||This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.||November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.|
|NIH||Research on Current Topics in Alzheimer's Disease and Its Related Dementias |
- PAR-19-070 (R01 Clinical Trial Optional)
- PAR-19-071 (R21 Clinical Trial Not Allowed)
|--||This invites applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of notices that are linked at the top of the funding opportunity websites.||November 12, 2021.|
|NIH||Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)||--||This invites exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.||November 17, 2021|
|NIH||Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)||--||This invites Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||November 17, 2021|
|NIH||Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)||--||This invites Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. A Cooperative Agreement means that after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.||November 17, 2021|
|NIH||Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)||--||The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.||November 17, 2021; March 17, 2022; July 19, 2022; November 7, 2022|
|NIH||NIH Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV||--||This solicits research to better understand the epidemiology and biology of oral HPV infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. |
RFA-DE-22-003 R01 Clinical Trial Not Allowed
- RFA-DE-22-004 R21 Clinical Trial Not Allowed
|November 18, 2021.|
|NIH||Emotion Regulation, Aging and Mental Disorder|
- PA-19-094 (R01 Clinical Trial Not Allowed)
- PA-19-095 (R21 Clinical Trial Not Allowed)
|--||This encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Applicants with preliminary data may wish to apply using the R01 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies utilizing existing data may wish to apply using the R21 mechanism.||Standard dates apply until January 8, 2022.|
|NIH||Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)||--||This supports projects that utilize open-access data available via the Bioinformatics Resource Centers (BRCs), alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. Projects focused on influenza, Mycobacterium tuberculosis (TB), antimicrobial resistance and malaria are encouraged although projects based on other pathogens relevant to National Institute of Allergy and Infectious Diseases will be supported.||Standard dates apply until January 8, 2022.|
|NIH||Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities||--||This seeks research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US. Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the US and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions.||This notice applies to receipt dates through January 8, 2022.|
|NIH||Bioengineering Research Grants (BRG)|
- PAR-19-158 (R01 Clinical Trial Not Allowed)
- PAR-19-159 (R01 Clincal Trial Required)
|--||The purpose is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.||Standard dates apply until January 8, 2022.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||February 15, 2022, July 14, 2022, February 14, 2023.|
|NIH||NIH Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)||Up to USD $450,000 for up to 3 years.||This is pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments.||March 1, 2022.|
|NIH||Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)||--||The purpose is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.||Standard dates apply until May 8, 2022.|
|NIH||NIH Dissemination and Implementation Research in Health||--||This supports innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.|
- PAR-19-274 (R01 Clinical Trial Optional)
- PAR-19-275 (R21 Clinical Trial Optional)
-PAR-19-276 (R03 Clinical Trial Not Allowed)
|Standard dates apply until May 8, 2022.|
|NIH||Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)||--||The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.||Applications will be accepted on a rolling basis, expiring on September 1, 2022.|
|NIH||Notice of Special Interest (NOSI): Research in the Emergency Setting||--||This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.||This notice applies to receipt dates through September 8, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children||--||This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children.||This notice applies to subsequent receipt dates through September 8, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to subsequent receipt dates through January 7, 2023.|
|NIH||Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023|
|NIH||Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration||--||The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD).||This notice applies to subsequent receipt dates through May 7, 2023.|
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)||--||This supports research that improves our understanding of the behavioral, social, and economic effects of the pandemic and to enhance our ability to control its spread. These effects will likely be particularly acute for NIH-designated health disparity populations , and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.||This notice applies to receipt dates May 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to receipt dates through January 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition||-||This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care||--||This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.||This notice applies to subsequent receipt dates through March 8, 2024.|
|NIH||NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes||--||National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.|
PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.
PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
|Standard dates apply until March 17, 2024.|
|NIH||NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)||--||This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.||Standard dates apply until May 8, 2024.|
|NIH||NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)||--||This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data.||Standard dates apply until May 8, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities||Up to USD $50,000 per year for up to 2 years.|| PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. |
PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
|Standard dates apply until May 8, 2024.|
|NIH||NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment||--||The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.|
PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional
|Standard dates apply until May 8, 2024.|
|NIH||NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities||--||The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.|
PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
|Standard dates apply until May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health||--||This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.||This notice applies to subsequent receipt dates through June 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning||--||This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.||This notice applies to subsequent receipt dates through September 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates through September 7, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Parent Announcements||--||NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)|
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)
Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
|Standard dates apply unless otherwise stated.|